Thank you, Madam Chair.
Thank you to all of you for coming. You've presented so much material, I'm not sure where to go this morning.
Could you table, for the committee, all existing Alzheimer's and dementia networks in Canada and internationally? If that could be broadened to cover neurological, that would be terrific. Could you also table with the committee the investments by Germany, the U.K., the U.S., and other countries so that we can see that direct comparison, please?
Mr. Ferdinand, you mentioned that Canadians don't have access to the latest drugs or choices, or we wait longer. You said that you could give us the specifics for Alzheimer's and Parkinson's disease. I was wondering if you could do that now, please.